DENVER, Colo. – If cancer patients are to receive optimal treatment, clinicians must have an accurate histologic classification of the tumor and know its genetic characteristics, said William D. Travis, M.D., attending thoracic pathologist, Department of Pathology, at Memorial Sloan Kettering Cancer Center in New York City. Dr. Travis made his remarks today at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC).
Mobile App IASLC Atlas of ALK Testing in Lung Cancer
March 2017 Newsletter
In this session, Prof. Keith Kerr updates a webinar first presented last year, on developments in personalized medicine for patients with lung cancer, the impact that this has had, and could have in the future, for those patients, and how the pursuit of biomarkers to predict response to targeted therapy has changed lung cancer diagnostics.